An interventional study of Left Bundle Branch Optimized CRT and Stimulation of the left bundle branch area (LBBAP) in Heart Failure Low Output, sponsored by Clinica Cardio VID. Enrolling by invitation at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Clinica Cardio VID · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Heart Failure with a site in Colombia — 7 open to participants now, 9 under way, 5 of them phase 3. Heart Failure · Colombia.
Among the 39 studies in Heart Failure with a site in Colombia, this one is the 33rd largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 39th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →7 of the 39 studies in Heart Failure with a site in Colombia are open now. Recruiting first, the newest first:
Amgen · Sites in Colombia, United States, Argentina and 32 more countries
Ages 18–99
Boehringer Ingelheim · Sites in Colombia, United States, Argentina and 26 more countries
Ages 18+
Boehringer Ingelheim · Sites in Colombia, United States, Argentina and 27 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Colombia, United States, Belgium and 27 more countries
Ages 29 days–17 yrs
Universidad de la Sabana · Sites in Colombia
Ages 18+
A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 21 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 3,388 across the 34 interventional studies, 2,169 across the 5 observational. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Clinica Cardio VID as lead sponsor.
Clinica Cardio VID has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Failure with a site in Colombia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07478081Universidad de la SabanamHealth Intervention to Support Self-care During the Hospital to Home Transition in Individuals With Heart Failure | 2027-06 |
| NCT07664189Clinica Cardio VIDLBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Heart Failure with a site in Colombia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this pilot clinical trial is to evaluate whether a novel cardiac resynchronization strategy, called LOT-CRT, is more effective than standard physiological pacing alone (LBBAP) in patients with heart failure.
This is a randomized, single-center, crossover pilot study involving 10 patients. All participants will receive a specialized pacemaker (CRT-P) with leads implanted in two specific areas: the Left Bundle Branch Area (LBBAP) and the Coronary Sinus (CS).
Because of the crossover design, each patient will serve as their own control, receiving two different pacing configurations in a random order: Active Phase (LOT-CRT): Simultaneous pacing of the left bundle branch and the coronary sinus. Control Phase (LBBAP alone): Pacing only the left bundle branch area. Each treatment phase will last 6 months, for a total follow-up of 12 months per patient.
By testing both strategies in the same patient, this study will help clinicians identify the most effective way to restore heart synchrony and improve clinical outcomes in patients with advanced heart failure and conduction delays.
This is a single-center, randomized, crossover pilot clinical trial. Each patient will serve as their own control. Following the successful implantation of a device capable of stimulating the LBBAP and the coronary sinus, participants will be randomly assigned to one of two treatment sequences:
Sequence A: LOT-CRT (LBBAP + CS) for 6 months, followed by LBBAP alone Sequence B: LBBAP alone for 6 months, followed by LOT-CRT Each treatment phase will last 6 months, followed by an end-point evaluation and a crossover. Since the hemodynamic effect of electrical stimulation is immediate, no washout period is required between phases.
This study was designed as an exploratory pilot study; therefore, no formal sample size calculation was performed. The number of patients enrolled is considered adequate to assess the feasibility of the procedure, the safety of the crossover design, and to identify preliminary signals of clinical and electrical efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LOT-CRT (LBBAP + CS) for 6 months, followed by LBBAP alone
Device: Left Bundle Branch Optimized CRT · Device: Stimulation of the left bundle branch area (LBBAP)
LBBAP for 6 months only, followed by LOT-CRT
Device: Left Bundle Branch Optimized CRT · Device: Stimulation of the left bundle branch area (LBBAP)
The CS lead will be implanted in a posterolateral or lateral vein using venography and standard IV delivery sheaths. Proper lead placement is confirmed by stable fixation, pacing capture, and absence of diaphragmatic pacing. The configuration for each phase of the study (LOT-CRT or LBBAP alone) will be assigned during randomization.
Also known as: LOT-CRT, Left bundle branch block pacing + coronary sinus pacing, LBBAP + CS, LOT-CRT Strategy, Combined stimulation, Maximized electrical resynchronization
The LBBAP lead will be implanted via a transvenous approach using the C315His sheath, targeting the left bundle branch area in the right ventricular septum, ideally between the basal septum and the mid-septal region. Criteria for confirming successful LBBAP capture will include: * Evidence of narrowing of the stimulated QRS complex compared to baseline. * Right bundle branch block morphology on the ECG-stimulus-to-R-wave time in V6 \<80 ms (if available). * Low and stable pacing threshold (\<1.5 V @ 0.4 ms). * Unipolar impedance between 400-1500 ohms. The CS lead will be implanted in a posterolateral or lateral vein using venography and standard IV delivery sheaths. Proper lead placement is confirmed by stable fixation, pacing capture, and absence of diaphragmatic pacing.
Also known as: Stimulation of the left branch only
Compare the effects of the LOT-CRT strategy versus left bundle branch block pacing (LBBAP) alone in each patient, comparing baseline to the end of the study FEVI, quality of life and functional class by NYHA.
Investigators will evaluate the following parameters in each patient: Left ventricular ejection fraction (LVEF) by echocardiography and electrocardiogram; functional capacity (NYHA class) using the 6-minute walk test and symptoms reported by the patient; quality of life (MLHFQ) using the MLHFQ quality of life scale
Time frame: 12 months
Change in end-systolic diameter
Absolute (mm) and relative (%) change in LVESV between baseline and 6 months.
Time frame: 12 months
QRS Duration
Absolute (ms) and relative (%) changes in the 12-lead ECG.
Time frame: 12 months
Change in end-diastolic diameter
Absolute (mm) and relative (%) change in LVEDV between baseline and 6 months.
Time frame: 12 months
NT-proBNP
Absolute (ng/mL) and relative (%) change in NT-proBNP from baseline to 6 months
Time frame: 12 months
Echocardiographic responder
LVEF ≥10% elevation or LVESV ≥15% decreased
Time frame: 12 months
Echocardiographic super-responder
LVEF ≥50% or LVESV ≥30% decrease
Time frame: 12 months
Composite Clinical Outcome
Cardiovascular Death or Hospitalization for Heart Failure
Time frame: 12 months
Procedural parameters
Thresholds, P- and R-waves, impedance of each electrode.
Time frame: 12 months
Procedure Time/Fluoroscopy
Total procedure time in minutes/ total fluoroscopy time in minutes.
Time frame: 12 months
Plan to share: Yes — Individual participant data, appropriately anonymized, that support the reported results will be made available to qualified researchers for the purposes of scientific research or meta-analysis. Requests must be addressed to the Principal Investigator and include a formal proposal. All requests will be subject to approval by the institutional ethics committee. As this is a study with a small sample size (10 patients), the protocol strictly enforces confidentiality; therefore, prior approval is always required to share these data. The data will be available from 6 months to 5 years following the publication of the main results.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: The data will be available from 6 months to 5 years following the publication of the main results.
Access criteria: Requests must be addressed to the Principal Investigator and include a formal proposal. All requests will be subject to approval by the institutional ethics committee.
Started Jun 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 12 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.